会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Combination treatment for impaired motor function in parkinson's disease
    • 帕金森病运动功能受损的组合治疗
    • US20060063810A1
    • 2006-03-23
    • US11215797
    • 2005-08-30
    • Juan VergezAlan LanierEthel FelederGlenn MeyerMarcelo RicciJoaquina Faour
    • Juan VergezAlan LanierEthel FelederGlenn MeyerMarcelo RicciJoaquina Faour
    • A61K31/452A61K31/343A61K31/137
    • A61K45/06A61K31/00A61K31/137A61K31/343A61K31/452A61K2300/00
    • The invention provides a method, and dosage form therefor, of treating impaired motor function associated with Parkinson's disease, anti-Parkinson's drug treatment, e.g. L-Dopa therapy, and/or dementia associated with Parkinson's disease. The invention includes the combined administration of an NMDA receptor antagonist and an antidepressant, e.g., the combination of amantadine and citalopram or venlafaxine, or an NMDA receptor antagonist and an anxiolytic agent, e.g., amantadine and buspirone or trazodone, for the amelioration of undesired tremors, akinesia, dyskinesia, or bradykinesia associated with one or more different disorders or diseases. The drugs can be included in a single dosage form. One embodiment includes a combination dosage form containing each drug in controlled release forms. Another embodiment includes a combination dosage form providing a controlled release of an NMDA receptor antagonist and a rapid release of a neuroactive agent after administration to a subject.
    • 本发明提供了治疗与帕金森病相关的运动功能障碍,抗帕金森氏病药物治疗的方法及其剂型。 左旋多巴治疗和/或与帕金森病有关的痴呆症。 本发明包括联合施用NMDA受体拮抗剂和抗抑郁药,例如金刚烷胺和西酞普兰或文拉法辛,或NMDA受体拮抗剂和抗焦虑剂(例如金刚烷胺和丁螺环酮或曲唑酮)的组合,用于改善不期望的颤抖 ,运动障碍,运动障碍或与一种或多种不同疾病或疾病相关的运动迟缓。 药物可以包含在单一剂型中。 一个实施方案包括含有受控释放形式的每种药物的组合剂型。 另一个实施方案包括提供NMDA受体拮抗剂的受控释放的组合剂型和在施用于受试者之后神经活性剂的快速释放。